Patents by Inventor Henry J. Haringsma

Henry J. Haringsma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11932854
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: March 19, 2024
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
    Publication number: 20220195433
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (MAO against target gene expression.
    Type: Application
    Filed: October 25, 2021
    Publication date: June 23, 2022
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11193126
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 7, 2021
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20180362977
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: April 6, 2018
    Publication date: December 20, 2018
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 9970005
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 15, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20160264964
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, Michael William Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 9260471
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 16, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James J. Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20130217756
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 22, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Mark Cancilla, James John Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham